Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus famitinib in advanced solid tumors
CTR20200719Phase 2Completed
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in Nonhematologic neoplasms, prostate cancer (PCa), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Apr 2020; status: completed.
02
Drugs
famitinib
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20200719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200719.